Widespread hepatitis B virus genotype G (HBV-G) infection during the early years of the HIV epidemic in the Netherlands among men who have sex with men by unknown
RESEARCH ARTICLE Open Access
Widespread hepatitis B virus genotype G
(HBV-G) infection during the early years of
the HIV epidemic in the Netherlands
among men who have sex with men
Marion Cornelissen1, Fokla Zorgdrager1, Sylvia M. Bruisten2, Margreet Bakker1, Ben Berkhout1
and Antoinette C. van der Kuyl1*
Abstract
Background: Hepatitis B virus (HBV) variants belong to different genotypes, A-J, whose worldwide distribution is
linked with geography, probably because viral spread was associated with ancient human migrations.
HBV genotype G (HBV-G) is an aberrant genotype with little sequence divergence, suggesting a recent origin.
HBV-G is strongly associated with certain risk groups such as intravenous drug users (IDUs) and men who have sex
with men (MSM), but hardly with geography. The origin and epidemiology of HBV-G remain unresolved, as is the
disease association.
Methods: To estimate the prevalence and possible time of introduction of HBV-G into the MSM community in
Amsterdam, the Netherlands, we have retrospectively analysed 226 blood serum samples from HBsAg positive MSM
enrolled in the Amsterdam Cohort Studies (ACS) on HIV infection and AIDS dating from 1984 to 1999 using
genotype-specific PCR assays.
Results: Of the 226 HBsAg-positive samples, 149 were HBV DNA positive. Of those, 104 were positive for HBV
genotype A (HBV-A) and five for HBV-G, and 40 showed a dual infection with both HBV-A and HBV-G. Being
HIV-infected was significantly associated with a reduced HBV DNA viral load in blood, but not with the prevalence
of HBV-G. Early virus already contained stop codons in the precore region and a 36 bp insertion in the core gene
which are the characteristics of HBV-G.
Conclusions: HBV-G was introduced before 1985 into the Amsterdam MSM community. Early isolates show very
limited sequence variation, confirming a low evolutionary rate. HBV-G acquisition was independent of HIV infection,
but being HIV-infected was significantly associated with a reduced HBV viral load in blood, indicating a beneficial
effect of early HIV infection in controlling HBV replication.
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Background
The hepadnavirus hepatitis B virus (HBV), a causative
agent of cirrhosis and liver cancer, is currently divided into
ten genotypes, named A-J, several subgenotypes and
recombinant forms whose dispersal is largely connected
with geography [1]. For instance, genotype A is the most
common variant in northern Europe, while genotype D is
more prevalent in eastern and southern Europe [1]. Geno-
type G, an aberrant HBV genotype without a clear
geographic association, is also present in certain risk
groups in Europe. The prevalence of HBV infection is low
in western Europe, e.g. HBsAg prevalence is <1 % in most
northern and western countries, and <0.5 % in the
Netherlands [2]. Higher rates of HBV infection in Europe
are apparent for migrants, men who have sex with men
(MSM) and intravenous drug users (IDUs). HBV-A2 is the
most prevalent HBV genotype in the Netherlands, in
particular among MSM [3]. Infections with HBV-G occur
in this risk group, but interestingly mainly as co-infections
with HBV-A2 and human immunodeficiency virus type 1
(HIV-1) [4]. Worldwide, HBV-G has almost exclusively
been found in HIV-infected MSM and IDUs [5–12], sug-
gesting a strong association with those risk groups.
Although HBV-G was also detected in two Mexican
children, the genotype is not endemic in Mexico and the
children were most likely infected either through blood
transfusion or close contact with a family member that
might belong to a risk group [13]. Mono-infections with
HBV-G are uncommon [14–16] as the virus apparently
does not replicate well due to a 12 amino acid insertion in
the Core protein that interferes with virion secretion and
stop codons in the precore region that prohibit HBeAg
expression [17, 18].
Rescue by a helper virus restores HBV-G production
such that it can even outcompete the helper genotype
[19–21]. Most HBV-G infections described are thus co-
infections with HBV genotype A in France [22], Spain [6],
Japan [7, 20], the USA [21, 23] and Canada [9], with HBV
genotypes A, C or D in Germany [24, 25], with HBV geno-
type A or H in Mexico [8], and with HBV genotype F in
Argentina and Brazil [11].
Global HBV-G isolates are closely related and show
very little sequence divergence [26], suggestive of a rela-
tively recent evolutionary origin [27], and/or a compara-
tively recent introduction in the risk groups. It is thus
possible that HBV-G was a recent introduction into the
Netherlands. Retrospective incidence data and sequence
analysis of early virus isolates could thus shed light on
the history of this peculiar HBV-G genotype. The
Amsterdam Cohort Studies (ACS) on HIV and AIDS
started in October 1984 with the inclusion of MSM and
IDUs from Amsterdam, the Netherlands [28]. The early
blood samples were collected before the era of effective
and extensive HBV vaccination and antiviral treatment.
Therefore, we set out to retrospectively determine the
prevalence of HBV-G and HBV-A infections in HBsAg-
positive participants of the ACS with or without HIV in-
fection that were collected from 1984 to 1999. In
addition, a characterization of certain genome character-
istics was performed for historical HBV-G isolates.
Methods
Patient material
The ACS started enrolling asymptomatic 18–65 year old
MSM with at least two sexual partners in the 6 months
prior to intake in October 1984. Participants were mainly
recruited through the gay press, advertisements and by
word of mouth. An undetermined number had taken part
in an earlier trial investigating the efficacy of an HBV
plasma-derived vaccine that was running from November
1980 till December 1981 [28]. Between April 1985 and
February 1988 only HIV-seronegative men could enter the
study. From February 1988 until December 1998,
admission was re-opened for HIV-infected individuals.
From the ACS, blood samples from MSM were selected
that met the following criteria: HBsAg-positive and prefera-
bly also HBcAb-positive and sampled before the year 2000
[29]. A total of 226 patient samples were HBsAg-positive,
of which 222 also tested HBcAb-positive at the same
moment. CD4+ T-cell counts at sampling date were avail-
able for 196 participants, both HIV-positive and HIV-
negative MSM. All blood samples have been stored at −80 °
C for the entire period; thaw-freeze cycles were limited to
0–1 during storage.
Real-time PCR assays
Viral DNA was isolated from serum samples with the
QIAamp UltraSens Virus Kit (QIAGEN, the Netherlands).
Single-tube real-time PCR reactions that specifically quan-
tify HBV genotype A or G DNA were performed as
described [4], for the primer sequences, see also Additional
file 1: Table S1. The primers and probes used are highly
specific for the targeted HBV genotype (either A or G) and
have a lower limit of detection of 5 copies per reaction
(=1000 copies/ml) of the targeted genotype in a background
of up to 108 copies of the non-targeted genotype [4].
Genotype-specific PCR assays
Real-time PCR results were confirmed using a genotype A
or G specific nested PCR. The first PCR spans the 3’end
of the pol gene and part of the X gene (nt 692–1823 from
the EcoRI site). The nested PCR amplifies a fragment of
762 base pair (bp) (nt 902–1664 from the EcoRI site), and
is able to detect 5–10 copies of input DNA.
Genotype-specific primers amplifying the precore region
were developed for HBV-C, D, F and H with the first PCR
amplifying a fragment spanning nt. 1728–2071 and a
nested PCR amplifying nt 1751–2034. All genotype-specific
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primer sequences are given in Additional file 1: Table S1.
The nested PCR’s detect 5–10 copies of the specific HBV-
DNA per reaction. Any amplified products were analysed
by sequencing (see below). Non-target genotypes were
sometimes amplified when the input DNA of the non-
targeted genotype was ≥105 copies/ml.
To investigate the presence of stop codons in the precore
gene and the 36 bp insertion in the core gene, a fragment of
232 (HBV-A) or 268 (HBV-G) bp, encompassing the
precore and core region of the viral genome (see Additional
file 1: Table S1 for primer sequences), was amplified with a
nested PCR that detects 5–10 copies of HBV-DNA per reac-
tion, from blood serum samples and directly sequenced with
the BigDye Terminator cycle sequencing kit (Applied
Biosystems, Foster City, CA, USA). Electrophoresis and data
collection were performed on an ABI PRISM 3100 genetic
analyser (Applied Biosystems, Foster City, CA, USA).
Sequences were assembled with CodonCode Aligner [30],
and aligned with reference HBV sequences from the NCBI
nucleotide database [31] using ClustalW implemented in
BioEdit Sequence Alignment Editor version 7.0.9 [32].
HBeAg analysis
HBeAg expression in apparently HBV-G mono-infected
samples was analysed using the Liaison® HBeAg chemilu-
minescence immunoassay (DiaSorin SpA, Saluggia, Italy).
Statistical analysis
Statistical analyses were performed in GraphPad Prism 5
(GraphPad Software, La Jolla, CA).
Results
Prevalence of HBV-G in MSM in Amsterdam 1984–1999
A total of 226 serum samples from the ACS that were
HBsAg-positive and in majority also HBcAb-positive
were retrospectively analysed for the presence of HBV-A
and/or HBV-G DNA using real-time PCR assays and a
confirmatory PCR with genotype-specific primers.
The majority of samples selected were from 1985 to
1986 (170/226 samples, 75 %) (Fig. 1). A total of 149/
226 (66 %) of the samples were HBV DNA positive
(Table 1), and of those, 40 samples (27 %) displayed a
dual infection with both HBV genotypes A and G, while
five sample appeared to be mono-infected with HBV-G.
Amplification of other “helper” HBV genotypes from
these samples remained negative with both type-specific
and more general primers.
In this cross-sectional analysis, HBV DNA prevalence
was slightly higher (73 %) in HIV-negative MSM than in
HIV-positive MSM (63 %), but this difference was not sta-
tistically significant (Chi-square test p > 0.1). Dual infections
with both HBV-A and HBV-G were more prevalent in
HIV-positive MSM (33 % vs. 17 % in HIV-negative MSM)
but this difference was again not significant (Chi-square test
p > 0.05). Mono-infections with HBV-G were equally
distributed between the two groups: 2 mono-infections
(4 %) with HBV-G in HIV-negative versus 3 mono-
infections (3 %) in HIV-positive MSM.
Surprisingly, HBV-A and HBV-G DNA was only
present in samples from 1985 to 1987 in HIV-negative
MSM, but not in subsequent years (Fig. 2a). For HIV-
positive MSM, HBV DNA could be detected in samples
up to 1997, although the numbers of positive samples
decreased over time (Fig. 2b). These findings correlate
well with the strongly declining numbers of individuals
after 1986 that met our selection criteria involving sero-
logical evidence of HBV infection (Fig. 1), and are in
line with an earlier report on a profound decline of the
HBV incidence in the ACS after the first years of its es-
tablishment [29].
Fig. 1 Number of Dutch MSM samples selected from the ACS with
regard to year of sampling. Numbers of blood serum samples
selected from the ACS are shown. Samples were selected when they
fulfilled the following criteria: originating between 1984 (start of the
ACS) and 1999, and having been tested HBsAg and preferably
HBcAb positive
Table 1 HBV-A and HBV-G DNA detection in blood serum
samples from Dutch MSM 1984-1999
HBV genotype
amplified






N = 152 N = 74
HBV-A 104 61 43
HBV-G 5 3 2





149 (66 %) 95 (63 %) 54 (73 %)
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Prevalence of HBV-G in MSM in Amsterdam in 1985 with
regard to their HIV status
Because HBV DNA prevalence decreases sharply after 1986
in HIV-negative MSM, the prevalence of HBV DNA in
blood was calculated for 1985, the year with the highest
number of HBV positive MSM, to compare values between
those infected and uninfected with HIV (Fig. 2). In 1985,
HBV-G DNA was detected in 9/40 (23 %) of the HBV DNA
positive/HIV-negative MSM and in 15/53 (28 %) of the
HBV DNA positive/HIV-positive MSM (Fisher’s exact test,
two-tailed, p > 0.1), implicating that HBV-G infection was
not more common among those infected with HIV than
those without HIV infection. Adding data for 1986, the only
other year with appreciable HBV DNA positivity for HIV-
uninfected men, did yield similar prevalence values for
HBV-G infection (21 % in HIV- uninfected versus 28 % in
HIV- infected MSM, Fisher’s exact test, two-tailed, p > 0.1).
HBV-G mono-infection and HBeAg expression
HBV-G does not express Hepatitis B “e” antigen (HBeAg),
probably due to its non-functional precore region [14, 15,
17]. So, in any HBV-G positive samples displaying HBeAg
positivity, expression is most likely due to co-infection
with another HBV genotype. Therefore, we measured
HBeAg in the five apparent HBV-G mono-infections, and
found it to be present in one of these five samples
(Table 2). Unfortunately, in the three samples from 1985
to 1991, dual infected samples used as controls were also
HBeAg-negative, suggesting that sample age and/or stor-
age conditions could have an effect on the assay, limiting
Fig. 2 Numbers of MSM that were HBV-A and/or HBV-G DNA positive with regard to year of sampling and HIV status. The numbers of MSM from
the ACS during 1984–1999 that tested either HBV-A, HBV-G or HBV-A and HBV-G positive using two genotype-specific real-time PCR assays
followed by a genotype-specific nested PCR to confirm the real-time PCR results. Results are shown in panel (a) for HIV-negative MSM (N = 74)
and in panel (b) (N = 95) for HIV-positive MSM
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its predictability. Alternatively, samples could be HBeAg-
negative due to preceding HBeAb seroconversion. From
the four samples tested from 1997, the dual infected sam-
ples and one of the apparently mono-infected samples (no.
ACS-970660) exhibited HBeAg positivity, whereas the
other mono-infected sample (no. ACS-971256) was nega-
tive for HBeAg, suggesting that it could represent a true
HBV-G mono-infection. Repeated attempts to amplify a
helper HBV genotype from samples ACS-850676, ACS-
850530, ACS-916078, ACS- 971256 that were HBeAg
negative and sample ACS-970660 that was HBeAg-positive,
failed. Using other samples from patient ACS-970660 col-
lected 14 days before and 29 days after sample ACS-970660
was obtained also did not result in the amplification of an-
other HBV genotype. Using forward and reverse primers
destined for specific genotypes in various combinations also
did not result in the amplification of PCR products of the
expected lengths for any of the samples.
HBV-G and HBV-A serum viral load in HIV-positive and
HIV-negative individuals
As HBV DNA detection was performed using a real-time
PCR assay, the viral load of the samples could be calcu-
lated. HBV-A, acting as a helper virus, is known to
increase the HBV-G viral load, therefore, the HBV-G viral
loads in mono- or dual infected samples should be ana-
lysed separately. However, mono-infection with HBV-G is
a rare phenomenon, which was also the case in the
present study. Therefore, we only analysed the HBV-G
viral load in HBV-A and HBV-G double-infected MSM.
For HIV-negative MSM, only samples from 1985 to 1986
yielded HBV DNA, therefore the HBV-G viral load com-
parisons were restricted to that period (Table 3). A log10
lower mean HBV-G viral load was found in HIV-infected
MSM, which was statistically significant (Student’s t-test,
two-tailed, p = 0.0063).
The HBV-A viral load was calculated from the real-time
PCR data for four groups of patients in 1985 and 1986 (N
= 112): those that were HIV-positive and either HBV-A
mono-infected (N = 44), or HBV-A and -G dual infected
(N = 17), as well as for these two groups without HIV infec-
tion (N = 42 and N = 9, respectively). The mean HBV-A
viral load was found to be significantly lower in the group
that carried all three viruses (HIV, HBV-A and HBV-G)
compared with the HIV-negative group that was infected
with HBV-A and HBV-G (Table 3, Student’s t-test, two-
tailed, p = 0.0008). Comparing the HIV-positive and
negative groups that were infected with HBV-A alone also
showed a significant difference between their mean HBV-A
viral load (Student’s t-test, two-tailed, p = 0.04).
A remarkable observation is that in the triple infected
group, a viral load in the higher range (>105 copies/ml)
was never measured in the 17 patients analysed, whereas a
viral load between 105 and 109 copies/ml was frequently
seen in those infected with HBV-A alone, irrespective of
their HIV status (not shown). In fact, in 12/44 (27 %) of
the HIV-positives and 19/42 (45 %) and 5/9 (56 %) of the
HIV-negatives infected with HBV-A or HBV-A and -G,
respectively, the viral load was between 105 and 109
copies/ml. An extremely high viral load (>109 copies/ml)
was only observed in persons infected with HBV-A without
HBV-G, irrespective of their HIV status. Of the HIV-
positives, 6/44 (14 %) and of the HIV-negative individuals
12/42 (29 %) carried a viral load >109 copies/ml.
Correlation of HBV-A and HBV-G serum viral loads
The HBV-A and HBV-G viral load in dual infected indi-
viduals (n = 40) is depicted in Fig. 3. In half of the cases,
viral loads for both genotypes are very similar with 20/
40 (50 %) samples showing less than one log10 difference
in viral load. The HBV-A viral load was significantly
higher than the HBV-G viral load in the other half of
cases. In no cases did the HBV-G viral load exceed the
HBV-A viral load by more than one log10 difference,
although there were two cases where the HBV-G viral
Table 2 HBeAg in HBV-G mono-infection
Patient no. Year HIV serology HBV genotype PCR HBV-A cps/ml HBV-G cps/ml HBeAg (PEI U/mLa) HBeAg result
ACS-850676 1985 NEG G — 2.69E + 02 <0.0100 NEG
ACS-850530 1985 NEG G — 1.67E + 02 <0.0100 NEG
ACS-916078 1991 POS G — 1.39E + 02 <0.0100 NEG
ACS-971256 1997 POS G — 3.14E + 04 <0.0100 NEG
ACS-970660 1997 POS G — 9.49E + 09 3.61 POS
ACS-850622 1985 NEG A/G 5.83E + 05 5.52E + 05 <0.0100 NEG
ACS-850626 1985 NEG A/G 1.44E + 05 3.85E + 03 <0.0100 NEG
ACS-916084 1991 POS A/G 7.22E + 03 8.01E + 02 <0.0100 NEG
ACS-972833 1997 POS A/G 5.59E + 08 2.36E + 08 7.57 POS
ACS-972876 1997 POS A/G 1.65E + 08 3.34E + 02 13.5 POS
aPaul Ehrlich Institute units/mL
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load was slightly higher than that of HBV-A. Both latter
samples were from HIV-positive individuals.
CD4+ T cell counts and HBV-DNA in HIV-positive
individuals
For 39 ACS participants without HIV infection and 96 par-
ticipants with HIV infection and measurable HBV DNA,
CD4+ T-cell counts at sampling date were available. Com-
parison of the mean CD4+ T-cell count between HIV-
negative and HIV-positive individuals showed a large
difference of around 300 cells/μl, which was statistically sig-
nificant (Student’s t-test, two-tailed, p < 0.0001) (Fig. 4), as
would be expected. There were no significant CD4+ T-cell
count differences with regard to single (HBV-A) or dual
infection (HBV-A +HBV-G), both in the HIV-negative or
positive groups (Fig. 4). Also, there was no significant
correlation between the HBV viral load in mono versus
dual infected HIV-positive participants (Spearman’s rank
correlation coefficient rs = −0.06, p = 0.66), suggesting that -
at least in this cohort-, CD4+ T-cell numbers are not
related to HBV replication level. Analysing samples from
the early years (1985–1986) of the ACS separately from
later years (1990–1997) did not change these results.
Molecular characteristics of HBV-G during 1985–1999: a
G1776A mutation in a subset of patients
For 29 samples from 45 HBV-G infected individuals, suffi-
cient quantities of the blood serum sample were available
to amplify a 268 bp fragment spanning the precore and
core region of the genome for sequence analysis. The se-
quences were investigated for the presence of the charac-
teristic features of present-day HBV-G, one or two stop
codons in the precore region and a 36 bp insertion into
the core gene. All sequences from 1985 till 1997 contained
these features, suggesting that HBV-G from 1985 was gen-
etically similar to the later isolates. The only sequence
variation observed was a single G1776A mutation that
was present in 15 HBV-isolates from 1985 to 1997 (Fig. 5).
Six HBV-G isolates carrying this mutation were from
HIV-negative MSM and 9 HBV-G isolates were from
HIV-positive MSM.
Discussion
In this study, we have retrospectively analysed the preva-
lence of HBV genotype G in MSM from the Amsterdam
area in the early years of the HIV epidemic and found it to
be widely present from 1985 onwards in HBV-seropositive
MSM. The early HBV-G isolates were genotypically highly
similar to later isolates and contained the distinctive char-
acteristics of HBV-G, being two stop codons in the pre-
core region precluding HBeAg expression and a 36 bp
insertion in the core gene. In 1985 and 1986, the preva-
lence of HBV-G was similar between HIV-positive and
HIV-negative MSM, suggesting that risk group and thus
risk behaviour is important for acquisition of the virus. Be-
ing HIV- infected apparently does not serve as an add-
itional risk factor. After 1986 there was a sharp decrease
in the HBV DNA positivity that was already observed as a
decline in seroprevalence during patient selection for the
present study. The steep decline in HBV prevalence has
been observed for the ACS in general. Van Houdt et al. re-
ported that the overall incidence of anti-HBc seroconver-
sion was highest in 1985–1986, declined afterwards, and
remained stable thereafter up to 2003, when routine vac-
cination was started for this risk group [29]. HBV-DNA
positivity in HIV-negative MSM disappeared after 1987,
although two HIV-negative samples from that period (dat-
ing to 1996 and 1999, respectively) were selected for this
study because of positive HBV serology. The decline in
Table 3 HBV-A and HBV-G viral load in HBV double- or mono-infected MSM from 1985 to 1986 with or without HIV infection
1985-1986 N HBV-A/G infected HBV-A/G infected N HBV-A mono- infected
Mean HBV-G viral load log10 (range) Mean HBV-A viral load log10 (range) Mean HBV-A viral load log10 (range)
HIV- negative samples 9 4.06 (2.96–5.74) 5.32 (3.73–8.76) 42 5.66 (1.30–9.46)
HIV- positive samples 17 2.94 (0.62–4.49) 3.69 (2.18–4.80) 44 4.53 (2.20–9.66)
p-value* 0.0063 0.0008 0.040
*Student’s t-test, two-tailed
Fig. 3 HBV-A and HBV-G serum viral load in dual infected
individuals. Log10 transformed HBV serum viral loads, as determined
using a two genotype-specific real-time PCR assays, are shown
for 40 Dutch MSM who were dually infected with HBV-A/HBV-G,
irrespective of HIV status, during 1985–1997. After 1986, all dually
infected MSM were HIV-positive
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Fig. 4 Mean CD4+ T-cell counts in ACS participants with or without HIV infection and measurable HBV-A or HBV-A/HBV-G DNA. The mean CD4+
T-cell counts are shown for HIV-negative/HBV-A DNA positive MSM (N = 30, mean 853 ± 68 cells/μl), HIV-negative/HBV-A + HBV-G DNA positive
MSM (N = 9, mean 848 ± 90 cells/μl), HIV-positive/HBV-A DNA positive MSM (N = 57, mean 534 ± 34 cells/μl), and HIV-positive/HBV-A + HBV-G DNA
positive MSM (N = 28, mean 483 ± 39 cells/μl), respectively. Statistical significance is indicated by p-values (Student’s t-test, two-tailed, NS = not
significant). CD4+ T-cell ranges are 290–1710 cells/μl for HIV-negative MSM and 90–1310 cells/μl for HIV-positive MSM
Fig. 5 Numbers of HBV-G isolates with or without the G1776A mutation during 1985–1997. A nested PCR amplifying nt 1751–2034 of the HBV
genome was sequenced for 29 HBV-G isolates to investigate the evolution of this region during 1985–1997. A G1776A mutation was detected
in 15 of the isolates dating to 1985–1993
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HBV positivity possibly relates to decreased risk behaviour
as anti-HBV vaccination was negligible at that time. It is
possible that the age of the samples could have influenced
our study, as some samples have been stored for almost
30 years. However, we believe that sample age did not in-
fluence our results, firstly because most samples that were
HBV DNA positive were from 1985, and secondly because
the real-time PCR amplifies very short DNA fragments,
and in general only amplification of longer fragments is af-
fected by DNA degradation.
HBV-G sequence variation in the 1985–1997 period was
extremely low. Two fragments of in total 1029 bp of the
3.2 kb genome were sequenced for 29 Dutch HBV-G iso-
lates and only a single nucleotide substitution, G1776A,
was found in 50 % of the isolates from 1985 to 1993 in
both HIV-negative and positive individuals. This specific
mutation is often seen in the chronic phase of other HBV
genotypes, which have been correlated to liver pathology
[17, 33]; it has not yet been reported in HBV-G sequences
obtained from other geographic regions than the
Netherlands. The G1776A mutation contributes to the
“late stage” genotype of HBV-G that also includes the 2
precore stop codons and the T1753C/A1762T/G1764A/
G1896A core promoter mutations that are fixed in HBV-
G genomes. HBV-G infection has been associated with
liver fibrosis [10, 22], although others found no such rela-
tion [34]. In mice, dual, but not single infection with
HBV-A and HBV-G or HBV-H and HBV-G leads to in-
creased liver fibrosis [35, 36]. It is possible that the
G1776A mutation occurred de novo in different patients,
but it seems more likely that these two strains were circu-
lating in Amsterdam at least since 1985. An HBV-G strain
from an HIV-positive patient presenting with acute HBV-
A and -G infection in Amsterdam in 2003 also did carry
this mutation [4], suggesting that the variant strain did
not disappear from the Amsterdam region after 1993.
The low sequence variation seen in HBV-G during 1985–
1997 is not unique for this specific genotype, as very little
nucleotide differences were reported for a 672 nt pre-S2
and S region fragment of HBV-A in the same cohort from
1985 till 2002 [29]. A recent phylogenetic analysis indeed
proposed a very low substitution rate for HBV [27].
Five apparent HBV-G mono-infections were detected in
MSM samples from 1985, 1991 and 1997. No other geno-
type commonly associated with HBV-G infection (e.g.
HBV-A, −C, −D, −F, or -H) could be amplified from these
samples. All five samples were HBsAg positive, which is not
incompatible with HBV-G mono-infection. HBsAg expres-
sion can be decreased or delayed in mono-G infections, but
it has frequently been reported to occur [14–16]. HBV-G
apparently does not express HBeAg [17], and therefore the
samples were tested for the presence of the HBV “e” anti-
gen. Indeed, four samples were HBeAg-negative, which
could be an indication, but not definite proof, of mono-
infection. In HBeAg-positive infection, expression leads to
HBeAb seroconversion and elimination of hepatocytes ex-
pressing HBeAg, and thus to disappearance of detectable
HBeAg (see: [37]). Acute HIV-1 infection can lead to a loss
of HBeAg, but none of our five patients were HIV serocon-
verters at the time of sampling, and two individuals were
actually HIV-negative. Control dual infected samples from
1985 and 1991 also showed no measurable HBeAg levels,
suggesting that sample age and/or storage condition could
have interfered with performance of the assay. Summariz-
ing, only one sample from 1997 could likely represent an
HBV-G mono-infection, as HBeAg expression in the other
sample from 1997 suggests the presence of a helper geno-
type. However, repeated attempts to amplify this virus
failed, even when using patient samples from an earlier or
later time point.
A cross-sectional analysis of the viral load of HBV-A
and HBV-G in MSM from the early years of the HIV epi-
demic in Amsterdam revealed that in 1985–1986, being
HIV-infected resulted in a significantly lower viral load of
both HBV-A and HBV-G compared with HIV-uninfected
MSM. It has been reported that acute HIV-1 infection re-
sults in decreased HBV DNA levels, suggesting that the
immune activation induced by HIV is beneficial for con-
trolling HBV replication [38, 39]. In some cases, the HBV
DNA viral load remained low for as long as two years after
acute HIV-1 infection [38]. In the ACS, MSM enrolled in
1985–1986 were not likely to be in the AIDS stage of HIV
infection as they had to be asymptomatic to be eligible for
inclusion. This may provide an explanation for the signifi-
cantly decreased HBV viral load in the HIV-positive
group. In this cohort, absolute CD4+ T-cell counts were
not related to HBV viral load, neither in mono-infected
nor in dual HBV-infected individuals. This suggests that
CD4+ T-cells are not significantly involved in suppression
of HBV replication. In a large multinational study of HBV
and HIV-infected individuals, low CD4+ T-cell counts
were related to high HBV DNA loads [40]. However, the
relation was best noticeable when CD4+ T-cell counts de-
clined to below 50 cells/μl, which is much lower than the
CD4+ T-cell counts in our patient selection. In addition,
in MSM with chronic HBV-infection an association be-
tween HIV infection and higher HBV levels has been re-
ported [41]. As the chronicity of HBV infection has not
been determined in our cohort, e.g. liver enzymes and
liver pathology were not investigated, this discrepant find-
ing might be related to the heterogeneous composition of
our selection with regard to the unidentified stages of both
HBV and HIV infections.
Conclusions
An analysis of the prevalence and characteristics of HBV
genotype G in 1984–1999 in a cohort of MSM in the
Netherlands was performed in the present study. The
Cornelissen et al. BMC Infectious Diseases  (2016) 16:268 Page 8 of 10
results show that HBV-G was already widely present
among Dutch MSM in 1985. In this cohort, HIV status
was not associated with HBV-G infection, but the HBV
viral load of both genotype A and G in mono-A or dual
A/G infected MSM was significantly lower in HIV-
infected men, confirming the beneficial effect of HIV
infection in controlling HBV replication. HBV-G isolates
from 1985 contain both genetic features reported for this
genotype: stop codons in the precore region and a
36 bp insertion in the core gene. HBV-G sequence
variation was extremely limited to a G1776A muta-
tion that was seen throughout the study period in ap-
proximately half of the patient isolates, suggesting the
circulation of two slightly divergent HBV-G lineages
among MSM in the Netherlands.
Additional file
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